Pair page
Bromantane with Selank
Mechanism-tag overlap and published literature for Bromantane and Selank, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
actoprotector-adamantane-derivative
anxiolytic-nootropictuftsin-analog
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Bromantane and Selank have published these mechanism-level observations. Not a co-administration recommendation.
Both Bromantane and Selank have anxiolytic properties through different mechanisms (GABAergic potentiation + trophic dopaminergic vs tuftsin-peptide immunomodulatory / anxiolytic). Combination provides calm-focus rather than agitation-focus — the distinctive Russian nootropic profile.
Quick facts
Bromantane
Selank
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2009 | Bromantane | Badyshtov BA, Makhnycheva AL, Kolik LG, Seredenin SB. Efficacy and safety of ladasten for treatment of asthenic disorders. Results of clinical trials. Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(5):24-28. (Phase III supporting Russian Ladasten approval.) | human trial, Phase 3 |
| 2006 | Bromantane | Vakhitova IuV, Iamidanov RS, Vakhitov VA, Seredenin SB. The effect of ladasten on gene expression in the rat brain. Mol Biol (Mosk). 2006;40(3):385-391. PMID: 16837899. PMID 16837899 | preclinical, in vivo |
| 1995 | Bromantane | Grekhova TV, Gaĭnetdinov RR, Sotnikova TD, Krasnykh LM, Kudrin VS, Sergeeva SA, Morozov IS, Rayevskiĭ KS. The effect of bromantane, a new immunostimulant and actoprotective preparation, on the release and metabolism of dopamine in the dorsal striatum of freely-moving rats. An in… | preclinical, in vivo |
| 1995 | Bromantane | Kudrin VS, Sergeeva SA, Krasnykh LM, Miroshnichenko II, Grekhova TV, Gainetdinov RR. The effect of bromantan on the dopamin- and serotoninergic systems of the rat brain. Eksp Klin Farmakol. 1995;58(4):8-11. PMID: 8555937. (Russian-language primary preclinical paper on neurotrans… PMID 8555937 | preclinical, in vivo |
| 2001 | Bromantane | Spasov AA, Bugaeva LI, Iezhitsa IN. Toxicological profile of adamantane derivatives. Eksp Klin Farmakol. 2001;64(2):77-80. (Toxicological characterization of the adamantane-derivative class.) | mechanism / discovery |
| 2012 | Bromantane | Oliynyk S, Oh S. The pharmacology of actoprotectors: practical application for improvement of mental and physical performance. Biomol Ther (Seoul). 2012;20(5):446-456. PMID: 24009833. (English-language review of the actoprotector class with bromantane as central example.) PMID 24009833 | review |
| 2004 | Bromantane | World Anti-Doping Agency. Prohibited List. International Standard. S6 Stimulants: bromantan. WADA. Various editions 2004–2026. (Continuous inclusion on the prohibited list since inception.) | regulatory / registry |
| 2008 | Bromantane | Voronina TA, Molodavkin GM, Sergeeva SA, Borliakov LM. Analysis of the neurophysiological mechanisms of anxiolytic effects of ladasten and afobazol. Eksp Klin Farmakol. 2008;71(3):3-7. PMID: 18651609. PMID 18651609 | research article |
| 2002 | Bromantane | Yakimovskii AF, Varshavskaya VM. Experimental analysis of psychopharmacological activity of bromantane. Bull Exp Biol Med. 2002;134(1):60-62. PMID: 12459869. PMID 12459869 | research article |
| 2001 | Bromantane | Morozov IS, Ivanova IA, Sergeeva SA, Petrov VI. Bromantan - a new immunostimulant and psychostimulant of the actoprotector series. Eksp Klin Farmakol. 2001;64(2):44-48. PMID: 11396112. PMID 11396112 | research article |
| 2008 | Selank | Zozulia AA, Neznamov GG, Syunyakov TS, et al. [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. PMID: 18454096. (Russian Phase… PMID 18454096 | human trial, Phase 3 |
| 2015 | Selank | Medvedev VE, Teresh'chenko OE, Israelyan AY, et al. [Optimization of therapy with traditional anxiolytic drugs in patients with anxiety-asthenic disorders]. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(4):33-40. | human study |
| 2008 | Selank | Uchakina ON, Uchakin PN, Miasoedov NF, et al. [Immunomodulatory effects of selank in patients with anxiety-asthenic disorders]. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(5):71-75. | human study |
| 2019 | Selank | Inozemtseva LS, Kudryavtseva NN, Bobkova NV, Dolotov OV, Gerasimova OA, Levitskaya NG, Kamensky AA, Andreeva LA, Myasoedov NF, Grivennikov IA. Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus… PMID 31625062 | preclinical, in vivo |
| 2017 | Selank | Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Biomed Res Int. 2017;2017:2875904. PMC5322660. | preclinical, in vivo |
| 2008 | Selank | Inozemtseva LS, Karpenko EA, Dolotov OV, Levitskaya NG, Kamensky AA, Andreeva LA, Grivennikov IA. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Dokl Biol Sci. 2008;421:241-243. PMID: 18841778. PMID 18841778 | preclinical, in vivo |
| 2007 | Selank | Semenova TP, Medvinskaia NI, Nesterova IV, Kozlovskaia MM. [Experimental analysis of the effect of Selank on the emotional and cognitive behavior of mice]. Zh Vyssh Nerv Deiat Im I P Pavlova. 2007;57(6):738-743. | preclinical, in vivo |
| 1998 | Selank | Seredenin SB, Kozlovskaia MM, Blednov IuA, Kozlovskii II. [Anxiolytic properties of Selank in BALB/c mice with differences in dopamine system reactivity]. Biull Eksp Biol Med. 1998;126(4):402-406. PMID: 9868709. PMID 9868709 | preclinical, in vivo |
| 2009 | Selank | Russian Federation State Register of Medicines. Selank — 0.15% intranasal solution. Approved 2009. | regulatory / registry |
| 2017 | Selank | Filatova E, Kasian A, Kolomin T, Rybalkina E, Alieva A, Andreeva L, Limborska S, Myasoedov N, Pavlova G, Slominsky P, Shadrina M. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Front Pharmacol. 2017;8:89. PMID… PMID 28316569 | research article |
| 2016 | Selank | Volkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, Slominsky P. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2016;7:31. PMID: 26903861. PMC4757669. PMID 26903861 | research article |
| 2003 | Selank | Kozlovskaya MM, Kozlovskii II, Val'dman EA, Seredenin SB. Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Neurosci Behav Physiol. 2003;33(7):639-643. PMID: 14552536. PMID 14552536 | research article |
Related pair pages
More research context
Frequently asked
Have Bromantane and Selank been studied together?
Researchers have published mechanistic-level co-administration discussion of Bromantane and Selank. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Bromantane and Selank share?
Bromantane and Selank do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Bromantane and Selank?
Bromantane: Not approved (US). Selank: Not approved. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Bromantane and Selank?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Bromantane profile and the Selank profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026